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DiffereNces iN Disease sPecific Hrqol iN rrms PatieNts iNitiateD oN 
oral Dmf or Platform tHeraPies iN euroPe aND us
Iyer R1, Pike J2, Rana J1, Petrillo J1, Lee A1, Jones E2
1Biogen, Cambridge, MA, USA, 2Adelphi Real World, Manchester, UK
BAckground: Multiple sclerosis (MS) is an unpredictable disease that can have 
physical, psychological, and social impacts, reducing health-related quality of life 
(HRQoL). oBjectives: To compare the HRQoL in patients initiated on delayed-
release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and prior 
approved interferon β -1a/b or glatiramer acetate (ABCRE) therapies. Methods: 
Data were identified from the Adelphi MS Disease Specific Programme, a cross-sec-
tional study of MS patients in five EU countries and the US. Relapsing Remitting MS 
(RRMS) patients were identified, receiving DMF or ABCRE therapies with treatment 
duration greater than 12 months. HRQoL was assessed using the Hamburg Quality of 
Life Questionnaire in MS (HAQUAMS), consisting of five domains (fatigue/thinking, 
mobility of lower limbs, mobility of upper limbs, social function and mood) in which 
higher scores indicate poorer HRQoL. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the HAQUAMS across 
DMF and ABCRE cohorts, utilizing a propensity score generated from age, gender, 
EDSS score at current treatment initiation, BMI, duration of current treatment, line 
of therapy, time since MS diagnosis, and number of comorbid conditions. results: 
A total of 252 (29 DMF, 223 ABCRE) patients completed the HAQUAMS question-
naire. The overall HAQUAMS score was significantly lower in DMF patients com-
pared to ABCRE patients (ATE= -0.45, p< 0.001, vs. 1.95). Significant differences were 
observed in four of the five subscales, as follows: fatigue/thinking (ATE= -0.47, 
p= 0.001, vs. 1.90), lower limb mobility (ATE= -0.43, p= 0.009, vs. 1.84), social function 
(ATE= -0.54, p< 0.001, vs. 2.05), and mood (ATE= -0.45, p< 0.001, vs. 2.40). The ATE for 
upper limb mobility score was not statistically significant (ATE= -0.15, p= 0.075, vs. 
1.38). conclusions: RRMS patients on DMF had significantly better HRQoL as 
measured by the HAQUAMS, versus RRMS patients on ABCRE therapies.
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a systematic review of tHe HumaNistic BurDeN of Disease iN 
PatieNts witH faBry Disease
Parini R1, Schiffmann R2, Fotheringham I3, Todorova L4
1San Gerardo Hospital, Monza, Italy, 2Baylor University Medical Center, Dallas, TX, USA, 3Oxford 
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oBjectives: Fabry disease is a rare, progressive, X-linked lysosomal storage disor-
der caused by deficiency of α -galactosidase A. Multiple major organs are affected, 
impacting on health-related quality of life (HRQoL). Symptomatic disease requires 
lifelong treatment with intravenous enzyme replacement therapy (ERT; two prod-
ucts available), which has been shown to improve long-term outcomes, delay organ 
damage and improve HRQoL. We present the results of a systematic review of the 
humanistic burden of Fabry disease. Methods: We conducted a systematic search 
of MEDLINE, Embase and congress proceedings to identify studies reporting general 
HRQoL in patients with Fabry disease. results: The search identified 30 relevant 
publications reporting data for ERT-treated and -untreated male and female adult 
and paediatric patients. The majority of studies assessed HRQoL using the 36-item 
Short-Form Health Survey (SF-36; n= 18) and/or 5-dimension European Quality of Life 
instrument (EQ-5D; n= 8). HRQoL was reduced compared with the general population 
(n= 12), and was worse than or similar to other chronic or progressive conditions 
(n= 8); furthermore, HRQoL deteriorated with age (n= 2) and with progressive dis-
ease severity (n= 1). Two clinical trials were identified (one placebo-controlled and 
one open-label) that described HRQoL improvements with ERT (agalsidase alfa). 
There were five analyses of registry data for patients receiving ERT: four studies 
demonstrated sustained HRQoL improvements with up to 5 years of agalsidase 
alfa treatment, and one study reported improvements after 1 and 2 years of agalsi-
dase beta therapy. In two small cohorts, overall HRQoL either improved in all SF-36 
domains after 10 years of ERT (n= 6 patients) or did not significantly decrease over 
7 years of ERT (n= 10 patients). conclusions: Patients with Fabry disease experi-
ence significant impairment in HRQoL, and the limited available data suggest that 
this improved while on ERT. Further studies are required to quantify treatment-
associated HRQoL outcomes.
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Brivaracetam as aDjuNctive tHeraPy of Partial-oNset seizures
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1UCB Pharma, Slough, UK, 2UCB Pharma, Raleigh, NC, USA
oBjectives: To assess the effect of brivaracetam (BRV), a new adjunctive therapy of 
partial-onset seizures (POS), on health-related quality of life (HRQoL). Methods: 
Data from three previously reported Phase III trials of BRV in adults with refrac-
tory POS (NCT00490035; NCT00464269; NCT01261325) were pooled. The QOLIE-31-P 
was collected at randomization and after the 12-week treatment period or early 
termination. The QOLIE-31-P is an epilepsy-specific instrument with seven sub-
scales and a Total score ranging from 0 (worse) to 100 (better HRQoL). Mean change 
from baseline to last observation was compared between BRV and placebo using 
ANCOVA controlling for baseline score. Percentages of meaningfully improved 
patients were calculated using published thresholds. results: There were 422, 
179, 324, and 235 patients in the placebo, BRV 50mg/day, 100mg/day, and 200mg/
day groups respectively. All mean (SD) changes were positive; they were similar for 
placebo and BRV for the Total score (+2.8 [12.7], +3.0 [14.0], +2.4 [14.0], +3.0 [12.1]) 
and most subscale scores. There was a BRV dose response for Energy/Fatigue (lower 
scores), Daily Activities and Seizure Worry (both higher scores). BRV 100mg/day 
showed significantly larger improvements than placebo (+7.3 [24.6] vs +5.0 [23.1]; 
p= 0.044) on the Seizure Worry subscale; this was the only significant result. 43.6%, 
41.7%, and 36.6% of BRV 50mg/day, BRV 100mg/day, 200mg/day patients experienced 
a meaningful improvement in the Total score, respectively; the rate was 38.6% for 
placebo. conclusions: Changes in HRQoL were small and generally comparable 
oBjectives: Multiple sclerosis (MS) is a chronic progressive neurologic disease 
and one of the most common causes of disability among young adults. Although 
the clinical manifestations and symptoms of MS are diverse, disease severity 
is generally measured by ambulation based Expanded Disease Severity Scale 
(EDSS). While EDSS captures well the level of disability due to the involvement of 
lower extremities and urinary bladder, its ability to capture other aspects such 
as fatigue and mental function are poor. The aim of this study was to explore the 
relationship between two patient-based measures, a self-administered EDSS and 
Multiple Sclerosis Impact Scale (MSIS-29), a psychometrically validated instru-
ment measuring the physical (20 items) and psychological (nine items) impact 
of MS. Methods: In total, 553 Finnish persons with MS (PwMS) drawn from the 
membership register of the national patient association completed a postal sur-
vey, including EDSS and MSIS-29. results: PwMS at every (0-9) impairment level 
of the EDSS scale were represented. The mean EDSS score was 4.0, indicating 
moderate disability. The physical impact of MS was strongly related to disease 
severity, with the scores ranging from 3.0 in the mildest disease (EDSS 0) to 76.2 
in the most severe disease (EDSS 8 – 9). The psychological impact increased syn-
chronously with the EDSS score in mild disease (EDSS 0 - 3) and peaked at EDSS 
5, declining thereafter from EDSS 5 to 7. In most severe disability (EDSS 8 – 9) the 
psychological impact of MS was equally high as in EDSS 4. conclusions: The 
subjective physical burden of MS increases steadily with self-assessed disease 
severity, whereas the psychological burden does not go hand in hand with the 
self-assessed severity of the disease.
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oBjectives: The Multiple Sclerosis International Quality of Life (MusiQoL) ques-
tionnaire is a self-administered, measure designed to evaluate the quality of life of 
patients with multiple sclerosis (MS). The MusiQoL was co-developed in 14 coun-
tries. It is composed of 31 items describing nine dimensions (activity of daily living, 
psychological well-being, symptoms, relationships with friends, relationships with 
family, relationships with health care system, sentimental and sexual life, coping, 
and rejection). The objective of this study is to present the challenges faced dur-
ing the translation of the MusiQoL in 57 additional languages representing seven 
language families. Methods: In each country, the translation process (linguistic 
validation) was conducted by a linguistic expert, using either the standard forward/
backward methodology or the adjusted process, including cognitive interviews with 
six patients. The basis for discussion was the concept list developed in collaboration 
with the authors. results: Semantic and cultural issues emerged during the pro-
cess. First, item 6 (had difficulty with your occupational activities: e.g., integration, 
interruption, limitation…?) could not be literally translated in most of the coun-
tries. Patients had difficulties understanding the words “integration, interruption, 
limitation.” The periphrasis and examples suggested in the concept list had to be 
used in most cases. Examples of solutions will be provided. Second, activities (e.g., 
shopping, going out to a movie, Do-It-Yourself, gardening) described in the original 
had to be adapted to the religious and social context of the target countries. For 
instance, “going out to a movie” had to be replaced by “going to an amusement park” 
in Saudi Arabia, since cinemas are forbidden for religious reasons. Other examples 
will be presented. conclusions: The initial simultaneous development of the 
MusiQoL in 14 countries minimized the challenges faced during the translation in 
57 additional languages. The collaboration with the developers and the patients’ 
interviews helped to solve the major issues.
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BAckground: Th EuroQol dimension (EQ-5D) is a widely used, standardised, qual-
ity of life measure producing health profildes, indices and states. oBjectives: 
To assess how people with Multiple Sclerosis (MS) on delayed-release dimethyl 
fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon 
β -1a/b or glatiramer acetate (ABCRE) therapies rate their quality of life, based 
on responses to the EQ-5D. Methods: Data were identified from the Adelphi 
MS Disease Specific Programme, a cross-sectional study of MS patients in five 
EU countries and the US. Relapsing Remitting MS (RRMS) patients were identi-
fied, receiving DMF or ABCRE therapies with treatment duration greater than 12 
months. General HRQoL was evaluated using the EQ-5D 3 level utility score, a 
standardized instrument providing a simple, generic measure of health, consisting 
of 5 questions measuring dimensions of health states (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression). A visual analog scale (VAS) is 
also included to measure overall health. Inverse-probability-weighted regression-
adjustment estimated average treatment effects (ATEs) on the EQ-5D across DMF 
and ABCRE cohorts, utilizing a propensity score generated from age, gender, EDSS 
score at current treatment initiation, BMI, duration of current treatment, line of 
therapy, time since MS diagnosis, and number of comorbid conditions. results: 
A total of 258 (30 DMF, 228 ABCRE) patients completed the EQ-5D questionnaire 
(mean age, 37.4 years; 31% male) with a mean time since diagnosis of 5.57 years. 
There was a significant difference in the EQ-5D utility score between the DMF and 
ABCRE cohorts (ATE: +0.075, p= 0.016, vs. 0.82 for ABCRE). Similarly, the overall VAS 
health reported by patients in the DMF cohort was significantly higher than the 
ABCRE cohort (ATE: +10.84, p< 0.001, vs 74.55 for ABCRE). conclusions: Patients 
on DMF reported significantly better functioning and quality of life compared with 
ABCRE patients, as measured by the EQ-5D.
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ing years per 1,000 patients. Predicted UK-wide benefits included the avoidance of 
2,097 transplants, 994 access procedures, approximately 2.5 million haemodialysis 
sessions and more than 900,000 peritoneal dialysis days, with gains of 71,500 QALYs, 
78,800 life years and 86,045 working years. conclusions: ADPKD-associated ESRD 
represents a significant burden to both patients and healthcare systems. Delaying 
disease progression through treatment could meaningfully impact this burden, 
reducing healthcare resource use, requirement for donor organs and the negative 
impact upon quality-of-life, life-expectancy and productivity.
PND84
muscular DystroPHy PatieNts witH severe reNal DysfuNctioN: 
aNalysis of ace-iNHiBitor use
Vlahiotis A1, Stott-Miller M1, Palmer LA2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA
oBjectives: Cardiovascular deterioration and renal dysfunction are significant 
complications for some muscular dystrophy (MD) patients. Although MD patients 
with cardiovascular problems may benefit from ACE-inhibitor treatment, there 
is some debate about whether this therapy is safe for use in patients with renal 
dysfunction. The objective of this study was to describe ACE-inhibitor treatment 
among MD patients with severe renal dysfunction, as they may be the most likely 
candidates for contraindication. Methods: We identified two cohorts of individu-
als aged 0-64 with a muscular dystrophy diagnosis between 1/1/2009 and 10/31/2013 
or 1/01/2009 and 10/31/2011 from an administrative claims database. Patients were 
continuously enrolled with benefits for 12 and 36 months, respectively, after the 
index date, defined as the first date of evidence of severe renal dysfunction--chronic 
kidney disease, renal failure or end stage renal disease. Subsequent ACE-inhibitor 
use was evaluated in the 12 and 36 months after index date. results: A total of 
11,515 MD patients with 12 months continuous enrollment, and 4,547 individuals 
with MD and 36 months continuous enrollment were identified, of which 14 -20% 
filled at least one prescription for an ACE-inhibitor. There were 340 (3%) patients 
with 12 months enrollment who had evidence of severe renal dysfunction, and 127 
(37%) of those filled a subsequent prescription for an ACE-inhibitor. There were 94 
(2%) patients with 36 months enrollment who had evidence of severe renal dys-
function, of which 50 (53%) filled at least one subsequent prescription for an ACE-
inhibitor. conclusions: Cardio-protective treatment with ACE-inhibitors among 
MD patients is significant. Although severe renal dysfunction is not highly prevalent 
in this population, 36%-49% with the condition were treated with an ACE-inhibitor, 
despite a possible contraindication, especially in patients with severe disease. New 
therapies in development which address underlying disease rather than complica-
tions may enable patients to avoid potential contraindications.
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costs associateD witH PatieNts DiagNoseD witH relaPsiNg 
remittiNg multiPle sclerosis takiNg oNce Daily fiNgolimoD caPsules 
iN tHe uNiteD states
Greene N1, Greene M2
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oBjectives: Fingolimod oral tablets were approved in the United States (US) in 
September 2010 for the treatment of relapsing remitting multiple sclerosis (RRMS). 
The objective of this study is to assess the costs associated with Fingolimod treat-
ment for patients diagnosed with RRMS in the US. Methods: A large US adminis-
trative retrospective claims database was used to identify patients diagnosed with 
RRMS and were prescribed Fingolimod between January 2010 to December 2012 were 
included in the study. All patients were ≥ 18 years of age and continuously enrolled 
in the same health plan for a year. Descriptive statistics and chi-square tests were 
performed on the data. results: There were a total of 28,477 patients that met 
the study inclusion criteria. Patients on average were charged $5270.93 ± 2760.33 
for their treatment with Fingolimod during the study period. However, the allowed 
amount by the health plan was $4624.41 ± 2070.65 and the actual paid amount was 
$4529.98 ± 2074.58. On average, patient’s deductible was $13.64 ± 186.88 and patient 
co-payment was $86.33 ± 316.10. For patients whose prescription was on their health 
plans formulary paid on average higher costs compared to patients who were not 
(paid amount $4679 vs $4317). Even though most of the patients were females, but 
they had overall lower costs compared to males (amount charged $4513 vs $4582, 
p> 0.05; co-payment $79 vs $106, p< 0.05). Patients who received treatment in the 
Midwest region of the USA had a higher costs compared to east, west and south 
regions (paid amount $4618 vs $4608 vs $4370 vs $4405). conclusions: The cost 
of Fingolimod treatment for RRMS patients is higher and costing the health plan 
around $3552 for 3 months. The cost of the drug treatment was higher in southern 
of the USA and males were paying more in general.
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over-PrescriPtioN of fiNgolimoD iN germaNy
Schoch G, Steimle T, Tamminga M, Blank S, Würdemann E
Techniker Krankenkasse, Hamburg, Germany
oBjectives: Fingolimod is an orally available immune-modulatory drug for treat-
ing relapsing-remitting Multiple Sclerosis (RRMS). It was approved by the European 
Medicines Agency (EMA) in March 2011. Some urgent safety warnings (e.g. progres-
sive multifocal leukoencephalopathy (PML) and cardiovascular events) have been 
reported in the meantime. Early benefit assessment by the Federal Joint Committee 
(G-BA) in 2012 and 2013 showed only additional benefit for a certain subgroup of 
patients. Therefore the use of Fingolimod has widely been discussed in Germany. 
We analyzed prescriptions of Fingolimod and the impact of Health Technology 
Assessment (HTA) and drug safety warnings. Methods: We used routine data of 
the Techniker Krankenkasse (TK), a large German sickness fund with more than 
8.2 million insured, from 2012 to 2014. We looked for prescriptions of disease-
modifying therapies (DMT) for patients with Multiple Sclerosis (MS). Diagnosis of 
MS was identified by G35 according to ICD-10. Considered DMT were Fingolimod, 
Glatiramer Acetate, Alemtuzumab, Natalizumab, Interferon beta-1a, Interferon beta-
between treatment groups. Differences reflected the known efficacy and safety 
profile of BRV. Where reported for other AEDs, changes from baseline and treatment 
group differences are similarly small, raising questions about the appropriateness of 
short-term fixed-dose trials as a source of HRQoL data for adjunctive AEDs in refrac-
tory patients. Long-term assessments may be more informative. Supported by UCB.
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Does crgs ProviDe ProPer guiDes for aN efficieNt PHarmaceutical 
PrescriPtioN iN alzHeimer PatieNts?
Caballer-Tarazona M1, Vivas-Consuelo D2, Escudero-Torrella J3, Macián-Izquierdo C1
1University of Valencia, Valencia, Spain, 2Politecnic University of Valencia, Valencia, Spain, 
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oBjectives: The aim of this paper is to analyze pharmaceutical expenditure in 
Alzheimer patients from a Europe southeastern region (Valencian Region (Spain)), 
by using the clustering patients system Clinical Risk Group (CRGs). We focused on 
obtaining more information about Alzheimer patients, stablishing a more accurate 
prediction of their resources consumption and individuating patterns of pharma-
ceutical consumption. Methods: A cross-sectional study of the inhabitants of 
Valencian region with a population of 5,000,000 was carried out, using data extracted 
from Electronic Health Records for 2013. A sample of 24641 Alzheimer individuals 
were identified. results: From our sample 29.4% men and 70.6% women were 
found. The annual average cost per Alzheimer patient is € 1709.051. By gender, 
women average cost is 1718,66 € while men average consumption is 1685,97 € . Age 
is the variable which most affect pharmaceutical cost variability, while severity 
levels are not capable to explain cost variability. conclusions: Valuable informa-
tion about pharmaceutical cost of Alzheimer patients was found. In contradiction 
to other diseases, for the Alzheimer case, levels of severity does not provide a clear 
explanation of pharmaceutical cost variability.
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DeveloPmeNt of a screeNiNg tool to suPPort iDeNtificatioN of 
PatieNts witH secoNDary Progressive multiPle sclerosis (sPms)
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oBjectives: Transition from RRMS to SPMS is difficult to diagnose. Here, we describe 
methodology for developing a screening tool that can help physicians to diagnose 
SPMS early. Methods: Tool will be developed along 3 steps: Quantitative research: A 
retrospective cross-sectional study to describe differentiating characteristics between 
SPMS and late RRMS patients using Adelphi Real World database. 2791 MS patient 
record forms from 125 neurologists (US) are available. Key variables will include demo-
graphics, MS history, treatment history, daily activities, symptoms and clinical charac-
teristics including MRI activity. Patients will be stratified based on EDSS and disease 
duration into: Early RRMS (control group), Late RRMS and Early SPMS. A multivariate 
regression analysis will identify the significant predictors of patient classification 
as ‘Late RRMS’ or ‘Early SPMS’ by physician. Qualitative research: (1) Open-ended 
qualitative interviews of patients (16 each in the US and Germany—8 RRMS and 8 
SPMS/country) and treating clinicians (8/country) to identify and characterize key 
differentiating features of these two MS phenotypes. (2) Integrating interviews with 
quantitative research to draft the tool. (3) Use of draft version by physicians treating 
SPMS patients. (4) Cognitive debriefing with physician. Tool validation: Sensitivity 
and specificity will be validated against reference tests in a 12Month prospective 
observational study in patients with late RRMS and SPMS after the implementation of 
the tool. results: Data collected will be used to generate a paper version of the tool 
that will track the disease experience of late RRMS patients periodically (relapse and 
recovery, symptoms, quality of life). After validating the paper version, an electronic 
version will be considered. A calculator will be added to the tool to predict likelihood 
of patient progression to SPMS. conclusions: Such a validated tool is expected to 
support physicians in more accurate and timely identification of SPMS patients to 
provide optimized clinical intervention.
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oBjectives: Autosomal dominant polycystic kidney disease (ADPKD) is charac-
terised by enlarged kidneys, declining renal function and ultimately progression 
towards end-stage renal disease (ESRD), with significant mortality, co-morbidity 
and resource implications. This study aimed to quantify the humanistic and health 
system burden of ADPKD in the UK, and the potential impact of ADPKD treatment 
that may delay progression to ESRD. Methods: ADPKD progression was predicted 
over a 50-year horizon using the ADPKD Outcomes Model. Patient profiles consistent 
with the CRISP longitudinal ADPKD outcomes trial were modelled using regression 
equations for renal decline derived from the TEMPO 3:4 study placebo arm. ESRD 
rates were drawn from UK published sources. Treatment-related reduction in the 
rate of renal decline was based on TEMPO 3:4 (tolvaptan: 31.6%). ESRD outcomes, 
quality-adjusted life-years (QALYs) and life-years accumulated were reported per 
1,000 patients, and scaled to the UK population. results: Without treatment, 927 
incident ESRD events were predicted per 1,000 patients; corresponding to 372 inci-
dent transplants, 435 dialysis access procedures and 4,707 dialysis years. Treatment 
was estimated to prevent 61 ESRD events per 1,000 patients, thereby avoiding 82 
transplants, 39 access procedures and 707 dialysis years, and accruing an additional 
2,788 QALYs and 3,075 life-years (undiscounted). Delay of ESRD beyond retirement 
age (65 years) was predicted in 16.6% of treated patients with 3,356 additional work-
